Back

Prognostic implication of sodium nitroprusside vasodilator test in pulmonary hypertension and left heart disease: insights from PUSHON registry.

1 September 2020 (08:30 - 08:30)
Organised by:
Congress Presentation Part of: The Conundrum of Pulmonary Hypertension due to Left Heart Disease – Can Science Help? Pulmonary Hypertension ESC Premium Access ESC Congress 2020

About the speaker

Photo
Doctor Paolo Boretto

University of Turin, Turin (Italy)

5 More presentations in this session

Presentation thumbnail
Combined pre- and post-capillary pulmonary hypertension defined by new criteria is worse prognosis group in patients with heart failure
Doctor T. Ibe (Saitama, JP)
Abstract Slides
Presentation thumbnail
Prognostic role of comorbidities in patients with pulmonary arterial hypertension
Doctor A. De Lorenzis (Bologna, IT)
Abstract Slides
Presentation thumbnail
Clinical characteristics and prognostic impact of pulmonary hypertension in heart failure with preserved ejection fraction: the PURSUIT HFpEF study
Doctor F. Sera (Suita, JP)
Abstract Slides
Presentation thumbnail
The association between atrial fibrillation and pulmonary embolism
Doctor E. Svennberg (Stockholm, SE)
Abstract Slides
Presentation thumbnail
Modeling survival using decision tree analysis in pulmonary hypertension due to left heart disease. the prognostic significance of PVR < 3WU when TAPSE < 16mm
Mr C. Fauvel (Rouen, FR)
Abstract Slides

Access the full session

Session thumbnail
The Conundrum of Pulmonary Hypertension due to Left Heart Disease – Can Science Help?

The Event

Event poster

ESC Congress 2020

1 September 2020 08:30 CET

ESC 365 is supported by

novartis Explore sponsored resources

ESC 365 is supported by

novartis Explore sponsored resources